D Westphal - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

D Westphal

Showing results (41-50 of 43) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 43 results.

Acta Neuropathologica Communications|August 6, 2024

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutationJ Steininger, C Buszello, R Oertel, et al.

The British Journal of Dermatology|June 29, 2021

High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinomaD Westphal, M Garzarolli, M Sergon, et al.

European Journal of Cancer (Oxford, England : 1990)|February 6, 2019

Sequence-dependent cross-resistance of combined radiotherapy plus BRAF<sup>V600E</sup> inhibition in melanomaB Shannan, J Matschke, H Chauvistré, et al.

Pageof 5

Search research articles

Showing results (41-50 of 43) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 43 results.

Acta Neuropathologica Communications|August 6, 2024

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutationJ Steininger, C Buszello, R Oertel, et al.

The British Journal of Dermatology|June 29, 2021

High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinomaD Westphal, M Garzarolli, M Sergon, et al.

European Journal of Cancer (Oxford, England : 1990)|February 6, 2019

Sequence-dependent cross-resistance of combined radiotherapy plus BRAF<sup>V600E</sup> inhibition in melanomaB Shannan, J Matschke, H Chauvistré, et al.

Pageof 5